Study shows majority of smokers re-ignite their habit following heart attack

(Medical Xpress)—A new study reveals that two-thirds of middle aged smokers who have been hospitalized for acute myocardial infarction resume smoking within twelve months, despite being treated with bupropion (sold as Zyban), which is prescribed to help those trying to quit because of its demonstrated capacity to reduce nicotine cravings and withdrawal symptoms without increasing heart rate or blood pressure the way nicotine replacement therapies will. This surprising finding, revealed in a study led by Dr. Mark Eisenberg, a cardiologist and epidemiologist at the Lady Davis Institute at the Jewish General Hospital, is published in the latest edition of the Journal of the American College of Cardiology

" was that suffering a heart attack served as a significant wake-up call inspiring smokers to quit. But Dr. Eisenberg is quick to add, "nobody had ever studied this population a year after the event. In fact, it may be that even more than two-thirds return to smoking, because those who agreed to participate in our study were more motivated than those who didn't want to be involved in a cessation trial." 

The study used a randomized sample of 392 patients, whose median age was 54 and who smoked an average of 23 cigarettes per day. Six months after beginning treatment, smoking abstinence was 39% in the bupropion group and 33% in the . At twelve months, the prevailing abstinence rates were 37% and 32%, respectively. One positive outcome among the persistent smokers was a dramatic reduction in their daily cigarette consumption to an average of eight per day, with no difference between groups.   

"Notwithstanding the relapse rate we observed, the patients' significant decrease in consumption suggests that a subset could be effectively re-targeted for therapy," Dr. Eisenberg pointed out. "While any reduction is positive, the health benefits of complete abstinence are significantly higher than even modest smoking. However, there is no escaping the power of a nicotine addiction combined with the social and behavioural aspects of smoking. It is very tough to quit and there is no magic bullet, in the form of a pill, that will make quitting easy." 

Funding for the study was provided by the Canadian Institutes of Health Research (CIHR) and the Heart and Stroke Foundation of Quebec (HSFQ). 

The study, "Bupropion for Smoking Cessation in Patients Hospitalized with " by Dr. Mark Eisenberg et al can be found in the Journal of the American College of Cardiology.

More information: www.journals.elsevier.com/jacc… ge-of-cardiology/%20

add to favorites email to friend print save as pdf

Related Stories

Smoking cessation therapies more effective than placebos

Jul 14, 2008

Six treatments for smoking cessation perform better than placebos — including varenicline (Chantix®), recently approved for use in Canada — states a team of researchers from McGill University and the University of Montreal ...

Common anxiety disorders make it tougher to quit cigarettes

Oct 25, 2010

Researchers may have pinpointed a reason many smokers struggle to quit. According to new research published in the journal Addiction, smokers with a history of anxiety disorders are less likely to quit smoking. The study, ...

Recommended for you

Vitamin D does not stop heart attack or stroke

21 hours ago

(Medical Xpress)—Taking vitamin D tablets cannot ward off heart attacks or stroke according to a new study from researchers at the University of East Anglia (UEA) published in the American Journal of Cl ...

New guidance on antithrombotic use in AF patients with ACS

22 hours ago

A new European joint consensus document on the use of antithrombotic drugs, including the non-vitamin K antagonist oral anticoagulants (NOACs), in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome ...

User comments